 MINNEAPOLIS, May 10, 2021 PRNewswire -- Bio-Techne Corporation NASDAQ:TECH today announced that Asuragen, a Bio-Techne brand, and scientific collaborators have published the results of a multisite evaluation study of the AmplideX PCRCE SMA Plus Kit that validates its performance in delivering accurate, reliable information to support carrier identification or diagnosis of spinal muscular atrophy SMA. These results were released in The Journal of Molecular Diagnostics. 